GleamWall
中文EN

TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD

Pharmaceutical Preparations · NYSE · SEC CIK 818686 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-16.4%
TTM net income YoY-28.9%
TTM EPS YoY-29.5%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR—

Margins

Gross margin65.8%
Operating margin10.2%
Net margin3.6%
FCF margin8.8%
EBITDA margin17.3%

Returns

ROE6.6%
ROA1.3%
ROIC (approx.)32.1%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets80.1%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.50x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue3.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$4.39B$4.14B$3.98B$1.50B$4.48B$4.18B$3.89B$4.23B
Cost of revenue$1.96B$1.99B$2.01B$2.06B$2.18B$2.07B$2.01B$2.11B
Gross profit$2.44B$2.15B$1.97B$2.66B$2.30B$2.10B$1.88B$2.12B
R&D expense$297.00M$970.00M$222.00M$267.00M$256.00M$244.00M$247.00M$247.00M
SG&A expense$298.00M$317.00M$304.00M$367.00M$317.00M$305.00M$297.00M$302.00M
Operating income$714.00M-$231.00M$652.00M$300.00M$882.00M$455.00M$519.00M-$29.00M
Pretax income$300.00M-$455.00M$437.00M$80.00M$646.00M$203.00M$294.00M-$247.00M
Income tax$66.00M$121.00M$67.00M-$390.00M$214.00M-$78.00M$74.00M$28.00M
Net income$233.00M-$576.00M$369.00M$480.00M$433.00M$282.00M$214.00M-$217.00M
EBITDA$959.00M$10.00M$891.00M$560.00M$1.13B$706.00M$763.00M$240.00M
EPS (basic)0.20-0.490.32—0.380.250.19—
EPS (diluted)0.20-0.490.31—0.370.240.18—
Weighted avg. shares (diluted)1.18B1.17B1.18B—1.16B1.16B1.16B—
Balance sheet
Cash & equivalents$4.08B$3.65B$3.74B$3.56B$2.20B$2.16B$1.70B$3.30B
Receivables$3.84B$3.49B$3.39B$3.71B$3.81B$3.56B$3.38B$3.06B
Inventory$3.17B$3.22B$3.18B$3.18B$3.32B$3.50B$3.25B$3.01B
Current assets$14.60B$13.76B$13.71B$13.95B$12.74B$12.62B$11.53B$12.55B
PP&E, net$3.75B$3.93B$4.00B$4.08B$4.82B$4.81B$4.63B$4.58B
Goodwill$15.74B$15.84B$15.82B$16.00B$15.95B$15.95B$15.48B$16.00B
Intangibles$3.30B$3.45B$3.61B$3.78B$3.94B$4.14B$4.19B$4.42B
Total assets$40.04B$39.86B$40.04B$40.75B$39.86B$40.13B$38.41B$39.33B
Current liabilities$15.43B$15.65B$13.53B$13.46B$11.49B$11.86B$11.16B$12.80B
Short-term debt$4.04B$4.50B$2.61B$1.82B$24.00M$464.00M$421.00M$1.78B
Total liabilities$32.06B$32.10B$31.81B$32.83B$32.60B$33.30B$32.15B$33.61B
Shareholders' equity$7.98B$7.75B$8.23B$7.91B$7.25B$6.83B$6.26B$5.37B
Cash flow statement
Operating cash flow$241.00M$411.00M-$40.00M$1.16B$369.00M$227.00M-$105.00M$575.00M
Capital expenditure$120.00M$104.00M$168.00M$142.00M$136.00M$96.00M$127.00M$129.00M
Free cash flow$121.00M$307.00M-$208.00M$1.02B$233.00M$131.00M-$232.00M$446.00M
Investing cash flow$210.00M-$491.00M$229.00M$165.00M$135.00M$236.00M$201.00M$202.00M
Financing cash flow$6.00M-$1.00M$13.00M$40.00M-$453.00M$6.00M-$1.74B-$674.00M
Depreciation & amortization$245.00M$241.00M$239.00M$260.00M$249.00M$251.00M$244.00M$269.00M
Stock-based compensation$38.00M$40.00M$43.00M$51.00M$34.00M$38.00M$34.00M$34.00M

Free plan shows the latest 8 periods; Pro shows all 76 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.